DailyStocks Stock Article Search

https://www.zacks.com/commentary/2223994/top-research-reports-for-johnson-johnson-walt-disney-uber?cid=CS-ZC-FT-research_daily-2223994 Feb 09, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and Uber Technologies, Inc. (UBER). 0

https://www.zacks.com/stock/news/2235489/j-j-jnj-secures-full-fda-nod-for-rybrevant-in-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2235489 Mar 04, 2024 - The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients. 0

https://www.zacks.com/stock/news/2236717/bayer-bayry-q4-earnings-top-crop-science-unit-drives-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2236717 Mar 06, 2024 - Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products. 0

https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322 Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use. 0

https://www.zacks.com/commentary/2240062/top-stock-reports-for-unitedhealth-johnson-johnson-oracle?cid=CS-ZC-FT-research_daily-2240062 Mar 13, 2024 - Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Oracle Corporation (ORCL). 0

https://www.zacks.com/stock/news/2242442/johnson-johnson-jnj-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2242442 Mar 18, 2024 - Johnson & Johnson (JNJ) closed the most recent trading day at $156.76, moving -0.9% from the previous trading session. 0

https://www.zacks.com/stock/news/2242244/bristol-myers-bmy-abecma-gets-odac-votes-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242244 Mar 18, 2024 - Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy. 0

https://www.fool.com/investing/2024/04/06/can-a-new-ceo-fix-boeing/?source=iedfolrf0000001 Apr 06, 2024 - We also talk with e.l.f. Beauty CEO Tarang Amin about how the company is succeeding. 0

https://www.zacks.com/stock/news/2252668/johnson-johnson-jnj-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2252668 Apr 09, 2024 - Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2253845/unlocking-q1-potential-of-johnson-johnson-jnj-exploring-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2253845 Apr 11, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024. 0